PTC

PTC Inc.
$141.02
-9.06 (-6.04%)
Mkt Cap 16.29B
Volume 2,119,748
52W Range 108.5-215.22
Sector Technology
Beta 1.00
EPS (TTM) 10.38 USD
P/E Ratio 13.59
Revenue (TTM) 2.95B USD
Rev Growth (5Y) +13.4%
EPS Growth (5Y) +40.2%
AlphaVal · Fair Value
What we estimate one share is worth
$117.31
Overvalued moderate signal
20.2% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
A-
Platform & Compounding FCF
82.8 / 100 composite
A platform business that compounds free cash flow — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 2.74B 2.30B 2.10B 1.93B 1.81B 1.46B 1.26B 1.24B 1.16B 1.14B 1.26B 1.36B
Net Income 734.00M 376.33M 245.54M 313.08M 476.92M 130.69M (27.46M) 51.99M 6.24M (54.47M) 62.10M 160.19M
EPS 6.12 3.14 2.07 2.67 4.08 1.13 -0.23 0.45 0.05 -0.48 0.54 1.34
Free Cash Flow 856.69M 731.62M 586.25M 409.38M 343.55M 202.56M 220.73M 208.77M 109.15M 156.98M 149.28M 279.28M
FCF / Share 7.14 6.11 4.95 3.49 2.94 1.75 1.88 1.79 0.94 1.38 1.29 2.34
Operating CF 867.70M 749.98M 610.86M 435.33M 368.81M 233.81M 285.14M 247.81M 134.59M 183.17M 179.90M 304.55M
Total Assets 6.62B 6.38B 6.29B 4.69B 4.51B 3.38B 2.66B 2.33B 2.36B 2.35B 2.21B 2.20B
Total Debt 1.37B 1.93B 1.89B 1.54B 1.65B 1.22B 669.13M 643.27M 712.41M 751.60M 668.12M 611.88M
Cash & Equiv 184.41M 265.81M 288.10M 272.18M 326.53M 275.46M 269.58M 259.95M 280.00M 277.94M 273.42M 293.65M
Book Value 3.83B 3.21B 2.68B 2.30B 2.04B 1.44B 1.20B 874.59M 885.44M 842.67M 874.71M 853.89M
Return on Equity 0.19 0.12 0.09 0.14 0.23 0.09 -0.02 0.06 0.01 -0.06 0.07 0.19
PTC News
PTC Inc. (PTC) Up 16.6% Since Last Earnings Report: Can It Continue?
Aug 28, 2026 08:36 AM · zacks.com
PTC Therapeutics to Participate in Upcoming Investor Conferences
Aug 27, 2026 04:00 AM · prnewswire.com
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
Aug 24, 2026 04:00 AM · prnewswire.com
PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential
Aug 24, 2026 01:31 AM · seekingalpha.com
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
Aug 16, 2026 07:02 AM · marketbeat.com
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
Aug 13, 2026 08:28 AM · benzinga.com
PTC Advances Leadership in AI-Driven Design with Launch of Onshape FeatureScript MCP Server
Aug 13, 2026 04:30 AM · prnewswire.com
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
Aug 12, 2026 12:01 PM · prnewswire.com
PTC Inc. (NASDAQ:PTC) Receives Average Recommendation of “Hold” from Brokerages
Aug 11, 2026 10:15 PM · defenseworld.net
Bank of America Corp DE Sells 39,720 Shares of PTC Inc. $PTC
Aug 08, 2026 11:44 PM · defenseworld.net